Nilsine Partners LLC increased its stake in Cardinal Health, Inc. (NYSE:CAH - Free Report) by 437.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,049 shares of the company's stock after acquiring an additional 4,924 shares during the period. Nilsine Partners LLC's holdings in Cardinal Health were worth $1,437,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Cardinal Health in the 2nd quarter worth $6,293,115,000. Wellington Management Group LLP grew its position in Cardinal Health by 247.5% during the second quarter. Wellington Management Group LLP now owns 14,860,271 shares of the company's stock valued at $3,530,206,000 after acquiring an additional 10,584,119 shares during the period. Norges Bank acquired a new stake in Cardinal Health during the fourth quarter worth about $790,344,000. Bank of America Corp DE acquired a new stake in Cardinal Health during the second quarter worth about $689,066,000. Finally, Legal & General Group Plc purchased a new position in shares of Cardinal Health in the 2nd quarter worth about $438,870,000. 87.17% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, CEO Deborah Weitzman sold 7,354 shares of the business's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $235.45, for a total value of $1,731,499.30. Following the transaction, the chief executive officer owned 77,901 shares in the company, valued at approximately $18,341,790.45. The trade was a 8.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Stephen M. Mason sold 35,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $236.40, for a total value of $8,274,000.00. Following the completion of the transaction, the chief executive officer directly owned 18,061 shares of the company's stock, valued at $4,269,620.40. This represents a 65.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 210,271 shares of company stock worth $49,626,657 over the last quarter. Company insiders own 0.12% of the company's stock.
Cardinal Health Stock Down 0.2%
Shares of NYSE:CAH opened at $246.67 on Monday. The company has a market capitalization of $57.37 billion, a price-to-earnings ratio of 34.12, a price-to-earnings-growth ratio of 1.49 and a beta of 0.51. The company has a 50 day moving average of $234.23 and a two-hundred day moving average of $219.17. Cardinal Health, Inc. has a 52-week low of $145.87 and a 52-week high of $258.30.
Cardinal Health (NYSE:CAH - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, topping analysts' consensus estimates of $2.42 by $0.49. The business had revenue of $63.67 billion for the quarter, compared to analysts' expectations of $65.15 billion. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $2.08 earnings per share. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. On average, equities analysts anticipate that Cardinal Health, Inc. will post 12.55 earnings per share for the current year.
Cardinal Health Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Thursday, October 1st will be given a $0.5158 dividend. This represents a $2.06 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Thursday, October 1st. Cardinal Health's dividend payout ratio is presently 28.49%.
Wall Street Analyst Weigh In
CAH has been the topic of several research analyst reports. Citigroup lifted their price objective on Cardinal Health from $265.00 to $280.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. UBS Group raised their price target on shares of Cardinal Health from $274.00 to $280.00 and gave the company a "buy" rating in a report on Wednesday, August 12th. Evercore reaffirmed an "outperform" rating and set a $270.00 price target on shares of Cardinal Health in a research report on Wednesday, August 12th. Wells Fargo & Company boosted their price objective on shares of Cardinal Health from $245.00 to $277.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 12th. Finally, Leerink Partners set a $292.00 price objective on shares of Cardinal Health in a research report on Tuesday, August 11th. Sixteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Cardinal Health has an average rating of "Moderate Buy" and a consensus price target of $266.56.
Read Our Latest Analysis on Cardinal Health
Cardinal Health Company Profile
(
Free Report)
Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.
The company's core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.
See Also
Want to see what other hedge funds are holding CAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardinal Health, Inc. (NYSE:CAH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Cardinal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardinal Health wasn't on the list.
While Cardinal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report